XML 106 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements Income and Comprehensive Income - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Total revenues $ 2,355.3 $ 1,887.1 $ 1,488.7
Operating expenses:      
Cost of revenues 34.0 39.7 23.2
Research and development 731.1 565.0 463.8
Acquired in-process research and development 12.5 143.9 0.0
Selling, general, and administrative 1,007.2 887.6 752.7
Total operating expenses 1,784.8 1,636.2 1,239.7
Operating income 570.5 250.9 249.0
Other (expense) income:      
Unrealized (loss) gain on equity investments (37.1) 28.4 30.8
Charges associated with convertible senior notes (138.4) 0.0 (70.0)
Interest income and other, net 91.0 52.8 4.1
Total other (expense) income, net (84.5) 81.2 (35.1)
Income before provision for income taxes 486.0 332.1 213.9
Provision for income taxes 144.7 82.4 59.4
Net income 341.3 249.7 154.5
Foreign currency translation adjustments, net of tax (1.1) 2.4 2.9
Unrealized gain (loss) on available-for-sale debt securities, net of tax (0.1) 12.5 (9.1)
Comprehensive income $ 340.1 $ 264.6 $ 148.3
Earnings per share, basic (in USD per share) $ 3.40 $ 2.56 $ 1.61
Earnings per share, diluted (in USD per share) $ 3.29 $ 2.47 $ 1.56
Weighted average common shares outstanding, basic (in shares) 100.4 97.7 95.8
Weighted average common shares outstanding, diluted (in shares) 103.7 101.0 98.9
Net product sales      
Total revenues $ 2,330.6 $ 1,860.6 $ 1,440.9
Collaboration revenue      
Total revenues $ 24.7 $ 26.5 $ 47.8